Literature DB >> 23459214

Value of Other Endovascular Techniques Among Patients with MERCI Device Failure during the Treatment of Acute Ischemic Stroke: What to do when MERCI fails?

Ameer E Hassan1, Mansoor M Aman, Saqib A Chauhdry, Mikayel Grigoryan, Wondwossen G Tekle, Gutavo J Rodriguez, Adnan I Qureshi.   

Abstract

BACKGROUND: The MERCI Retrieval system (Concentric Medical, Mountain View, CA) was the first FDA -approved device for mechanical thrombectomy in patients with acute ischemic stroke. It remains one of the most commonly used devices today despite its failure to restore blood flow in approximately 50% of the occlusions after technically successful deployment and retrieval. It remains unclear whether additional endovascular techniques or continued use of MERCI device can achieve recanalization post- MERCI failure.
OBJECTIVE: To analyze the outcome of continued MERCI retriever use compared with other endovascular techniques after initial failure.
METHODS: Failure of MERCI retriever was defined by successful deployment and retrieval of MERCI across target occlusion without recanalization in a single pass.. Pre- and post- treatment cerebral angiogram was classified using the Qureshi Grading Scale (QGS). Recanalization was defined by a reduction in ≥ 1 QGS grade between pre- and post- treatment cerebral angiogram in the Qureshi Grading Scale (QGS).We ascertained and compared the angiographic and clinical results with continued use of MERCI retriever or other endovascular techniques in patients following MERCI failure.
RESULTS: A total of 40 patients (53% men) had MERCI retrieval in this cohort with a mean age (±standard deviation) of 66.8 years ± 16 years and a mean admission National Institutes of Health Stroke Scale (NIHSS) score of 16.8 ± 6.7. Of the 40 patients treated with MERCI retrieval, there were 26 patients with MERCI failure. In group 1, there were 11 patients who underwent continued MERCI use and group 2 consisted of 15 patients who underwent an alternate endovascular technique. There was no significant difference in age, risk factors, or outcomes between the groups. The rate of recanalization (82% versus 80%, p=1.0), asymptomatic intra cerebral hemorrhage (18% versus 13%, p =0.77) and favorable outcome at discharge (27% versus 20%, p =0.66) were similar amongst the two groups.
CONCLUSIONS: Continued attempts using the MERCI device did not result in higher recanalization rates when compared to alternate endovascular treatment modalities following initial MERCI failure. Both techniques produced comparable rates of recanalization and favorable outcome.

Entities:  

Keywords:  Merci retrieval; endovascular treatment; intra-arterial thrombolysis; mechanical thrombectomy

Year:  2013        PMID: 23459214      PMCID: PMC3584818     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  20 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

3.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

4.  Measurements of acute cerebral infarction: a clinical examination scale.

Authors:  T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

5.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.

Authors:  D O Williams; J Borer; E Braunwald; J H Chesebro; L S Cohen; J Dalen; H T Dodge; C K Francis; G Knatterud; P Ludbrook
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

6.  Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study.

Authors:  Adnan I Qureshi; Amir M Siddiqui; M Fareed K Suri; Stanley H Kim; Zulfiqar Ali; Abutaher M Yahia; Demetrius K Lopes; Alan S Boulos; Andrew J Ringer; Mustafa Saad; Lee R Guterman; L Nelson Hopkins
Journal:  Neurosurgery       Date:  2002-11       Impact factor: 4.654

7.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

8.  New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke.

Authors:  Adnan I Qureshi
Journal:  Neurosurgery       Date:  2002-06       Impact factor: 4.654

Review 9.  Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence.

Authors:  William L Baker; Jennifer A Colby; Vanita Tongbram; Ripple Talati; Isaac E Silverman; C Michael White; Jeffrey Kluger; Craig I Coleman
Journal:  Ann Intern Med       Date:  2011-01-17       Impact factor: 25.391

10.  Recovery of motor function after stroke.

Authors:  R Bonita; R Beaglehole
Journal:  Stroke       Date:  1988-12       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.